CoChat

The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis

Open access
Zinatizadeh, Mohammad Reza, Miri, Seyed Rouhollah, Zarandi, Peyman Kheirandish, Chalbatani, Ghanbar Mahmoodi, Rapôso, Catarina, Mirzaei, Hamid Reza, Akbari, Mohammad Esmaeil, Mahmoodzadeh, Habibollah · 2021 · Genes & Diseases
Cited by 94

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Hippo Tumor Suppressor Pathway is the main pathway for cell growth that regulates tissue enlargement and organ size by limiting cell growth. This pathway is activated in response to cell cycle arrest signals (cell polarity, transduction, and DNA damage) and limited by growth factors or mitogens associated with EGF and LPA. The major pathway consists of the central kinase of Ste20 MAPK (Saccharomyces cerevisiae), Hpo (Drosophila melanogaster) or MST kinases (mammalian) that activates the mammalian AGC kinase dmWts or LATS effector (MST and LATS). YAP in the nucleus work as a cofactor for a wide range of transcription factors involved in proliferation (TEA domain family, TEAD1-4), stem cells (Oct4 mononuclear factor and SMAD-related TGFβ effector), differentiation (RUNX1), and Cell cycle/apoptosis control (p53, p63, and p73 family members). This is due to the diverse roles of YAP and may limit tumor progression and establishment. TEAD also coordinates various signal transduction pathways such as Hippo, WNT, TGFβ and EGFR, and effects on lack of regulation of TEAD cancerous genes, such as KRAS, BRAF, LKB1, NF2 and MYC, which play essential roles in tumor progression, metastasis, cancer metabolism, immunity, and drug resistance. However, RAS signaling is a pivotal factor in the inactivation of Hippo, which controls EGFR-RAS-RAF-MEK-ERK-mediated interaction of Hippo signaling. Thus, the loss of the Hippo pathway may have significant consequences on the targets of RAS-RAF mutations in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.gendis.2019.11.003

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 157

  1. Bronte, 2015, New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?, Oncotarget, 6, 24780, 10.18632/oncotarget.4959 · DOI · Paper page
  2. Kranenburg, 2001, Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists, Oncogene, 20, 1540, 10.1038/sj.onc.1204187 · DOI · Paper page
  3. Magalhaes, 2012, Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins, Br J Pharmacol, 165, 1717, 10.1111/j.1476-5381.2011.01552.x · DOI · Paper page
  4. Ratner, 2015, A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor, Nat Rev Cancer, 15, 290, 10.1038/nrc3911 · DOI · Paper page
  5. Raaijmakers, 2009, Specificity in Ras and Rap signaling, J Biol Chem, 284, 10995, 10.1074/jbc.R800061200 · DOI · Paper page
  6. Chan, 2013, PLCϵ and the RASSF family in tumour suppression and other functions, Adv Biol Res, 53, 258
  7. Brown, 2009, Protein scaffolds in MAP kinase signalling, Cell Signal, 21, 462, 10.1016/j.cellsig.2008.11.013 · DOI · Paper page
  8. Claperon, 2007, KSR and CNK: two scaffolds regulating RAS-mediated RAF activation, Oncogene, 26, 3143, 10.1038/sj.onc.1210408 · DOI
  9. White, 2009, IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis, FEBS Lett, 583, 1817, 10.1016/j.febslet.2009.05.007 · DOI · Paper page
  10. Teis, 2006, p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis, J Cell Biol, 175, 861, 10.1083/jcb.200607025 · DOI · Paper page
  11. Romano, 2014, Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling, Nat Cell Biol, 16, 673, 10.1038/ncb2986 · DOI
  12. Dhomen, 2007, New insight into BRAF mutations in cancer, Curr Opin Genet Dev, 17, 31, 10.1016/j.gde.2006.12.005 · DOI · Paper page
  13. Hafner, 2010, Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors, Proc Natl Acad Sci USA, 107, 20780, 10.1073/pnas.1008365107 · DOI
  14. Junttila, 2010, Selective activation of p53-mediated tumour suppression in high-grade tumours, Nature, 468, 567, 10.1038/nature09526 · DOI · Paper page
  15. Feldser, 2010, Stage-specific sensitivity to p53 restoration during lung cancer progression, Nature, 468, 572, 10.1038/nature09535 · DOI · Paper page
  16. Tan, 2014, Functions of TAp63 and p53 in restraining the development of metastatic cancer, Oncogene, 33, 3325, 10.1038/onc.2013.287 · DOI · Paper page
  17. Oren, 2010, Mutant p53 gain-of-function in cancer, Cold Spring Harb Perspect Biol, 2, 10.1101/cshperspect.a001107 · DOI · Paper page
  18. Irvine, 2015, Control of organ growth by patterning and hippo signaling in Drosophila, Cold Spring Harb Perspect Biol, 7, 10.1101/cshperspect.a019224 · DOI · Paper page
  19. Rawat, 2015, Regulation of mammalian Ste20 (mst) kinases, Trends Biochem Sci, 40, 149, 10.1016/j.tibs.2015.01.001 · DOI · Paper page
  20. Couzens, 2013, Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions, Sci Signal, 6, 10.1126/scisignal.2004712 · DOI · Paper page
  21. Hamilton, 2009, ATM regulates a RASSF1A-dependent DNA damage response, Curr Biol, 19, 2020, 10.1016/j.cub.2009.10.040 · DOI
  22. Avruch, 2009, Rassf family of tumor suppressor polypeptides, J Biol Chem, 284, 11001, 10.1074/jbc.R800073200 · DOI · Paper page
  23. Bayram, 2014, Association between RASSF1A Ala133Ser polymorphism and cancer susceptibility: a meta-analysis involving 8,892 subjects, Asian Pac J Cancer Prev APJCP, 15, 3691, 10.7314/APJCP.2014.15.8.3691 · doi:10.7314/apjcp.2014.15.8.3691
  24. Wu, 2010, Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients, Cancer Res, 70, 9721, 10.1158/0008-5472.CAN-10-1493 · DOI
  25. Yuan, 2015, Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival, Int J Cancer, 137, 638, 10.1002/ijc.29429 · DOI
  26. van der Weyden, 2012, Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis, Cancer Res, 72, 3817, 10.1158/0008-5472.CAN-11-3343 · DOI
  27. Matallanas, 2007, RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein, Mol Cell, 27, 962, 10.1016/j.molcel.2007.08.008 · DOI · Paper page
  28. Harvey, 2013, The Hippo pathway and human cancer, Nat Rev Cancer, 13, 246, 10.1038/nrc3458 · DOI · Paper page
  29. Matallanas, 2011, Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras, Mol Cell, 44, 893, 10.1016/j.molcel.2011.10.016 · DOI
  30. Takahashi, 2005, Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers, Clin Cancer Res, 11, 1380, 10.1158/1078-0432.CCR-04-1773 · DOI · Paper page
  31. Seidel, 2007, Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma, Mol Carcinog, 46, 865, 10.1002/mc.20317 · DOI · Paper page
  32. Grawenda, 2015, Clinical utility of RASSF1A methylation in human malignancies, Br J Canc, 113, 372, 10.1038/bjc.2015.221 · DOI
  33. Vlahov, 2015, Alternate RASSF1 transcripts control SRC activity, E-cadherin contacts, and YAP-mediated invasion, Curr Biol, 25, 3019, 10.1016/j.cub.2015.09.072 · DOI
  34. Gregorieff, 2015, Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer, Nature, 526, 715, 10.1038/nature15382 · DOI · Paper page
  35. Gordon, 2013, The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury, PLoS One, 8, 10.1371/journal.pone.0075483 · DOI
  36. Halder, 2011, Hippo signaling: growth control and beyond, Development, 138, 9, 10.1242/dev.045500 · DOI · Paper page
  37. Zhang, 2014, Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma, Sci Signal, 7, 10.1126/scisignal.2005049 · DOI · Paper page
  38. Avruch, 2012, Protein kinases of the Hippo pathway: regulation and substrates, Semin Cell Dev Biol, 23, 770, 10.1016/j.semcdb.2012.07.002 · DOI · Paper page
  39. O'Neill, 2004, Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1, Science, 306, 2267, 10.1126/science.1103233 · DOI · Paper page
  40. Volodko, 2014, RASSF tumor suppressor gene family: biological functions and regulation, FEBS Lett, 588, 2671, 10.1016/j.febslet.2014.02.041 · DOI · Paper page
  41. Polesello, 2006, The Drosophila RASSF homolog antagonizes the hippo pathway, Curr Biol, 16, 2459, 10.1016/j.cub.2006.10.060 · DOI · Paper page
  42. Avruch, 2006, Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases, Methods Enzymol, 407, 290, 10.1016/S0076-6879(05)07025-4 · DOI
  43. Yu, 2015, Cardiac hypertrophy induced by active Raf depends on Yorkie-mediated transcription, Sci Signal, 8, 10.1126/scisignal.2005719 · DOI
  44. Tapon, 2002, Salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines, Cell, 110, 467, 10.1016/S0092-8674(02)00824-3 · DOI · Paper page
  45. Rushworth, 2006, Regulation and role of Raf-1/B-Raf heterodimerization, Mol Cell Biol, 26, 2262, 10.1128/MCB.26.6.2262-2272.2006 · DOI · Paper page
  46. Hergovich, 2009, Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling, Biofactors, 35, 338, 10.1002/biof.47 · DOI
  47. Muller-Taubenberger, 2014, Regulation of a LATS-homolog by Ras GTPases is important for the control of cell division, BMC Cell Biol, 15, 10.1186/1471-2121-15-25 · DOI
  48. Anguera, 2008, Characterization of two Mst1-deficient mouse models, Dev Dynam, 237, 3424, 10.1002/dvdy.21764 · DOI
  49. Oh, 2009, Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse, Mol Cell Biol, 29, 6309, 10.1128/MCB.00551-09 · DOI · Paper page
  50. Du, 2014, Mst1 and mst2 are essential regulators of trophoblast differentiation and placenta morphogenesis, PLoS One, 9, 10.1371/journal.pone.0090701 · DOI
  51. St John, 1999, Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction, Nat Genet, 21, 182, 10.1038/5965 · DOI · Paper page
  52. McPherson, 2004, Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity, EMBO J, 23, 3677, 10.1038/sj.emboj.7600371 · DOI · Paper page
  53. Das Thakur, 2010, Ajuba LIM proteins are negative regulators of the Hippo signaling pathway, Curr Biol, 20, 657, 10.1016/j.cub.2010.02.035 · DOI · Paper page
  54. Sun, 2013, Ajuba family proteins link JNK to Hippo signaling, Sci Signal, 6, 10.1126/scisignal.2004324 · DOI · Paper page
  55. Reddy, 2013, Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins, Dev Cell, 24, 459, 10.1016/j.devcel.2013.01.020 · DOI · Paper page
  56. Graves, 1998, Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1, EMBO J, 17, 2224, 10.1093/emboj/17.8.2224 · DOI · Paper page
  57. Graves, 2001, Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis, J Biol Chem, 276, 14909, 10.1074/jbc.M010905200 · DOI · Paper page
  58. Ura, 2007, Activation of the c-Jun N-terminal kinase pathway by MST1 is essential and sufficient for the induction of chromatin condensation during apoptosis, Mol Cell Biol, 27, 5514, 10.1128/MCB.00199-07 · DOI
  59. Densham, 2009, MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability, Mol Cell Biol, 29, 6380, 10.1128/MCB.00116-09 · DOI · Paper page
  60. Danovi, 2008, Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis, Cell Death Differ, 15, 217, 10.1038/sj.cdd.4402226 · DOI
  61. Tomlinson, 2010, JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis, Cell Death Dis, 1, 10.1038/cddis.2010.7 · DOI · Paper page
  62. Genevet, 2011, The Hippo pathway and apico-basal cell polarity, Biochem J, 436, 213, 10.1042/BJ20110217 · DOI · Paper page
  63. Yang, 2014, Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration, Cell Signal, 26, 343, 10.1016/j.cellsig.2013.11.012 · DOI
  64. Hilton, 2008, KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling, Biochim Biophys Acta, 1783, 383, 10.1016/j.bbamcr.2007.12.007 · DOI
  65. Heidary Arash, 2014, Arhgef7 promotes activation of the Hippo pathway core kinase Lats, EMBO J, 33, 2997, 10.15252/embj.201490230 · DOI · Paper page
  66. Zhang, 2009, YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway, Nat Cell Biol, 11, 1444, 10.1038/ncb1993 · DOI · Paper page
  67. Kim, 2013, cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes, EMBO J, 32, 1543, 10.1038/emboj.2013.102 · DOI · Paper page
  68. Yu, 2013, Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation, Genes Dev, 27, 1223, 10.1101/gad.219402.113 · DOI · Paper page
  69. Dumaz, 2005, Integrating signals between cAMP and the RAS/RAF/MEK/ERK signaling pathways. Based on the anniversary prize of the Gesellschaft Fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels, FEBS J, 272, 3491, 10.1111/j.1742-4658.2005.04763.x · DOI · Paper page
  70. Mauviel, 2012, Integrating developmental signals: a Hippo in the (path) way, Oncogene, 31, 1743, 10.1038/onc.2011.363 · DOI
  71. Dong, 2007, Elucidation of a universal size-control mechanism in Drosophila and mammals, Cell, 130, 1120, 10.1016/j.cell.2007.07.019 · DOI · Paper page
  72. Xin, 2011, Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size, Sci Signal, 4, 10.1126/scisignal.2002278 · DOI · Paper page
  73. He, 2015, The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression, EMBO Mol Med, 7, 1426, 10.15252/emmm.201404976 · DOI · Paper page
  74. Garcia-Rendueles, 2015, NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition, Cancer Discov, 5, 1178, 10.1158/2159-8290.CD-15-0330 · DOI · Paper page
  75. Harris, 2010, The molecular pathology of cancer, Nat Rev Clin Oncol, 7, 251, 10.1038/nrclinonc.2010.41 · DOI · Paper page
  76. Zinatizadeh, 2019, The Role and Function of Ras-association domain family in Cancer: A Review, Genes Dis, 6, 378, 10.1016/j.gendis.2019.07.008 · DOI
  77. Yasunami, 1996, A novel family of TEA domain-containing transcription factors with distinct spatiotemporal expression patterns, Biochem Biophys Res Commun, 228, 365, 10.1006/bbrc.1996.1667 · DOI
  78. Lin, 2017, Regulation of the hippo pathway transcription factor TEAD, Trends Biochem Sci, 42, 862, 10.1016/j.tibs.2017.09.003 · DOI · Paper page
  79. Chen, 1994, Transcriptional enhancer factor-1 disruption by a retroviral gene trap leads to heart-defects and embryonic lethality in mice, Genes Dev, 8, 2293, 10.1101/gad.8.19.2293 · DOI · Paper page
  80. Kaneko, 2007, Transcription factor TEAD2 is involved in neural tube closure, Genesis, 45, 577, 10.1002/dvg.20330 · DOI · Paper page
  81. Sawada, 2008, Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival, Mol Cell Biol, 28, 3177, 10.1128/MCB.01759-07 · DOI · Paper page
  82. Yagi, 2007, Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development, Development, 134, 3827, 10.1242/dev.010223 · DOI · Paper page
  83. Nishioka, 2008, Tead4 is required for specification of trophectoderm in pre-implantation mouse embryos, Mech Dev, 125, 270, 10.1016/j.mod.2007.11.002 · DOI · Paper page
  84. Nishioka, 2009, The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass, Dev Cell, 16, 398, 10.1016/j.devcel.2009.02.003 · DOI · Paper page
  85. Ota, 2008, Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling, Development, 135, 4059, 10.1242/dev.027151 · DOI · Paper page
  86. Jacquemin, 1996, A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain, J Biol Chem, 271, 21775, 10.1074/jbc.271.36.21775 · DOI · Paper page
  87. Jiang, 2000, Cooperative binding of TEF-1 to repeated GGAATG-related consensus elements with restricted spatial separation and orientation, DNA Cell Biol, 19, 507, 10.1089/10445490050128430 · DOI · Paper page
  88. Anbanandam, 2006, Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain, Proc Natl Acad Sci USA, 103, 17225, 10.1073/pnas.0607171103 · DOI · Paper page
  89. Li, 2015, Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes, Mol Syst Biol, 11, 10.15252/msb.20145504 · DOI · Paper page
  90. Xiao, 1991, Cloning, expression, and transcriptional properties of the human enhancer factor tef-1, Cell, 65, 551, 10.1016/0092-8674(91)90088-G · DOI · Paper page
  91. Zhang, 2009, TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition, J Biol Chem, 284, 13355, 10.1074/jbc.M900843200 · DOI · Paper page
  92. Mahoney, 2005, The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members, Biochem J, 388, 217, 10.1042/BJ20041434 · DOI · Paper page
  93. Chen, 2004, Transcription cofactor Vgl-2 is required for skeletal muscle differentiation, Genesis, 39, 273, 10.1002/gene.20055 · DOI
  94. Koontz, 2013, The hippo Eector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression, Dev Cell, 25, 388, 10.1016/j.devcel.2013.04.021 · DOI · Paper page
  95. Chen, 2004, Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes, J Biol Chem, 279, 30800, 10.1074/jbc.M400154200 · DOI · Paper page
  96. Pobbati, 2012, Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes, Structure, 20, 1135, 10.1016/j.str.2012.04.004 · DOI · Paper page
  97. Honda, 2017, Vestigial-like 2 contributes to normal muscle fiber type distribution in mice, Sci Rep, 7, 10.1038/s41598-017-07149-0 · DOI
  98. Figeac, 2019, VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle, J Cell Sci, 132, 10.1242/jcs.225946 · DOI
  99. Kim, 2015, Transcriptional Co-repressor function of the hippo pathway transducers YAP and TAZ, Cell Rep, 11, 270, 10.1016/j.celrep.2015.03.015 · DOI · Paper page
  100. Jiao, 2017, VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer, Nat Commun, 8, 10.1038/ncomms14058 · DOI · Paper page
  101. Beyer, 2013, Switch enhancers interpret TGF-beta and Hippo signaling to control cell fate in human embryonic stem cells, Cell Rep, 5, 1611, 10.1016/j.celrep.2013.11.021 · DOI · Paper page
  102. Liu, 2016, Tead and AP1 coordinate transcription and motility, Cell Rep, 14, 1169, 10.1016/j.celrep.2015.12.104 · DOI · Paper page
  103. Park, 2015, Alternative Wnt signaling activates YAP/TAZ, Cell, 162, 780, 10.1016/j.cell.2015.07.013 · DOI · Paper page
  104. Lai, 2013, BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ, Cell Signal, 25, 1720, 10.1016/j.cellsig.2013.05.002 · DOI
  105. Zhang, 2009, YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway, Nat Cell Biol, 11, 1444, 10.1038/ncb1993 · DOI · Paper page
  106. Song, 2015, The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer, Clin Cancer Res, 21, 2580, 10.1158/1078-0432.CCR-14-2191 · DOI · Paper page
  107. Feng, 2017, Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells, Oncogene, 36, 5829, 10.1038/onc.2017.188 · DOI · Paper page
  108. Van Rensburg, 2018, The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1, Cancer Res, 78, 1457, 10.1158/0008-5472.CAN-17-3139 · DOI · Paper page
  109. Miao, 2017, YAP regulates PD-L1 expression in human NSCLC cells, Oncotarget, 8, 114576, 10.18632/oncotarget.23051 · DOI · Paper page
  110. Neto-Silva, 2010, Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap, Dev Cell, 19, 507, 10.1016/j.devcel.2010.09.009 · DOI · Paper page
  111. Rajbhandari, 2018, Cross-cohort analysis identifies a TEAD4-MYCN positive feedback loop as the core regulatory element of high-risk neuroblastoma, Cancer Discov, 8, 582, 10.1158/2159-8290.CD-16-0861 · DOI · Paper page
  112. Moroishi, 2015, A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis, Genes Dev, 29, 1271, 10.1101/gad.262816.115 · DOI · Paper page
  113. Park, 2016, Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma, Hepatology, 63, 159, 10.1002/hep.28223 · DOI · Paper page
  114. Holden, 2018, Targeting the hippo pathway and cancer through the TEAD family of transcription factors, Cancers, 10, 10.3390/cancers10030081 · DOI · Paper page
  115. Pobbati, 2013, Emerging roles of TEAD transcription factors and its coactivators in cancers, Cancer Biol Ther, 14, 390, 10.4161/cbt.23788 · DOI · Paper page
  116. Knight, 2008, TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer, Br J Canc, 99, 1849, 10.1038/sj.bjc.6604774 · DOI
  117. Liang, 2014, Expression of hippo pathway in colorectal cancer, Saudi J Gastroenterol, 20, 188, 10.4103/1319-3767.133025 · DOI · Paper page
  118. Liu, 2016, Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner, Oncogene, 35, 2789, 10.1038/onc.2015.342 · DOI
  119. Zhou, 2017, TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis, Oncogene, 36, 6518, 10.1038/onc.2017.257 · DOI
  120. Zhou, 2013, Effects of the hippo signaling pathway in human gastric cancer, Asian Pac J Cancer Prev APJCP, 14, 5199, 10.7314/APJCP.2013.14.9.5199 · DOI
  121. Han, 2008, DNA copy number alterations and expression of relevant genes in triple-negative breast cancer, Genes Chromosomes Cancer, 47, 490, 10.1002/gcc.20550 · DOI
  122. Wang, 2015, The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27(Kip1), Oncotarget, 6, 17685, 10.18632/oncotarget.3779 · DOI
  123. Korkola, 2006, Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo dierentiation of human male germ cell tumors, Cancer Res, 66, 820, 10.1158/0008-5472.CAN-05-2445 · DOI · Paper page
  124. Skotheim, 2006, Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes, Cell Oncol, 28, 315
  125. Zhang, 2018, TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma, Cancer Cell Int, 18, 10.1186/s12935-018-0675-z · DOI
  126. Schutte, 2014, Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma, Transl Oncol, 7, 309, 10.1016/j.tranon.2014.02.005 · DOI · Paper page
  127. Fernandez-L, 2009, YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation, Genes Dev, 23, 2729, 10.1101/gad.1824509 · DOI · Paper page
  128. Bokhovchuk, 2019, Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy, FEBS J, 286, 2381, 10.1111/febs.14817 · DOI
  129. Fossdal, 2004, A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration), Hum Mol Genet, 13, 975, 10.1093/hmg/ddh106 · DOI · Paper page
  130. Sun, 2015, Prognostic Value of yes-associated protein 1 (YAP1) in various cancers: a meta-analysis, PLoS One, 10, 10.1371/journal.pone.0135119 · DOI
  131. Feng, 2016, Prognostic significance of TAZ expression in various cancers: a meta-analysis, OncoTargets Ther, 9, 5235, 10.2147/OTT.S109540 · DOI
  132. Jiao, 2014, A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer, Cancer Cell, 25, 166, 10.1016/j.ccr.2014.01.010 · DOI · Paper page
  133. Park, 2013, Regulation of the Hippo pathway and implications for anticancer drug development, Trends Pharmacol Sci, 34, 581, 10.1016/j.tips.2013.08.006 · DOI · Paper page
  134. Haemmerle, 2017, Platelets reduce anoikis and promote metastasis by activating YAP1 signaling, Nat Commun, 8, 10.1038/s41467-017-00411-z · DOI · Paper page
  135. Zhao, 2012, Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis, Genes Dev, 26, 54, 10.1101/gad.173435.111 · DOI · Paper page
  136. Lee, 2017, Fluid shear stress activates YAP1 to promote cancer cell motility, Nat Commun, 8
  137. Chen, 2012, LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker, Nat Med, 18, 1511, 10.1038/nm.2940 · DOI · Paper page
  138. Guo, 2016, RAR gamma downregulation contributes to colorectal tumorigenesis and metastasis by derepressing the hippo-Yap pathway, Cancer Res, 76, 3813, 10.1158/0008-5472.CAN-15-2882 · DOI · Paper page
  139. Li, 2017, A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis, Nat Cell Biol, 19, 106, 10.1038/ncb3464 · DOI · Paper page
  140. Qiao, 2017, YAP regulates actin dynamics through ARHGAP29 and promotes metastasis, Cell Rep, 19, 1495, 10.1016/j.celrep.2017.04.075 · DOI · Paper page
  141. Lee, 2017, YAP1 is essential for tumor growth and is a potential therapeutic target for EGFR-dependent lung adenocarcinomas, Oncotarget, 8, 89539, 10.18632/oncotarget.19647 · DOI
  142. Lee, 2018, Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas, Sci Rep, 8, 271, 10.1038/s41598-017-18527-z · DOI · Paper page
  143. Xu, 2015, Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib, Cell Biosci, 5, 10.1186/2045-3701-5-7 · DOI · Paper page
  144. Yamauchi, 2019, Hippo pathway in mammalian adaptive immune system, Cells, 8, 10.3390/cells8050398 · DOI
  145. Zhang, 2014, Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma, Sci Signal, 7, 10.1126/scisignal.2005049 · DOI · Paper page
  146. Rozengurt, 2018, Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival, Signal Transduct Targeted Ther, 3, 10.1038/s41392-017-0005-2 · DOI · Paper page
  147. Kapoor, 2014, Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer, Cell, 158, 185, 10.1016/j.cell.2014.06.003 · DOI · Paper page
  148. Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
  149. Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X · DOI · Paper page
  150. Fisher, 2017, Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells, Oncotarget, 8, 110257, 10.18632/oncotarget.22628 · DOI
  151. Kim, 2016, Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation, EMBO J, 35, 462, 10.15252/embj.201592081 · DOI · Paper page
  152. Murakami, 2017, Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma, Oncogene, 36, 1232, 10.1038/onc.2016.288 · DOI · Paper page
  153. Feng, 2014, Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through atrio-regulated rho GTPase signaling circuitry, Cancer Cell, 25, 831, 10.1016/j.ccr.2014.04.016 · DOI · Paper page
  154. Yu, 2014, Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP, Cancer Cell, 25, 822, 10.1016/j.ccr.2014.04.017 · DOI · Paper page
  155. Garcia-Ocana, 2014, “RAS”ling beta cells to proliferate for diabetes: why do we need MEN?, J Clin Investig, 124, 3698, 10.1172/JCI77764 · DOI
  156. Chamberlain, 2014, Menin determines K-RAS proliferative outputs in endocrine cells, J Clin Investig, 124, 4093, 10.1172/JCI69004 · DOI
  157. Kok, 1997, Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes, Adv Cancer Res, 71, 27, 10.1016/S0065-230X(08)60096-2 · DOI · Paper page

Cited by

See all 94

Metadata

Authors
Zinatizadeh, M. R., Miri, S. R., Zarandi, P. K., Chalbatani, G. M., Rapôso, C., Mirzaei, H. R., Akbari, M. E., & Mahmoodzadeh, H.
Venue
Genes & Diseases
Publisher
Elsevier BV
Published
2021-01
Volume
8
Issue
1
Pages
48-60
ISSN
2352-3042 (ISSN-L)
OpenAlex
W2992254622
Cited by
94
References
31
FWCI
1.88
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis. https://app.cochat.ai/papers/10.1016/j.gendis.2019.11.003
The paper
Zinatizadeh, M. R., Miri, S. R., Zarandi, P. K., Chalbatani, G. M., Rapôso, C., Mirzaei, H. R., Akbari, M. E., & Mahmoodzadeh, H. (2021). The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis. Genes & Diseases. https://doi.org/10.1016/j.gendis.2019.11.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.